Evaluation of the Pharmacotherapeutic Efficacy of Cycloartane Glycosides in Comparison to Lovastatin in Rabbits with Experimental Atherosclerosis

The cycloartane glycosides cyclocarposide and cyclosieversioside F prevent an increase in the blood serum contents of cholesterol, triglycerides, and total fraction of pre-β- and β-lipoproteins in rabbits with atherosclerosis. They increase the ratio of α-cholesterol to total cholesterol and reduce...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutical chemistry journal 2022-08, Vol.56 (5), p.587-591
Main Authors: Syrov, V. N., Kaipnazarov, T. N., Tsaruk, A. V., Islamova, Zh. I., Shakhmurova, G. A., Egamova, F. R., Ramazanov, N. Sh, Khushbaktova, Z. A.
Format: Article
Language:English
Subjects:
Antilipemic agents
Antioxidants
Atherosclerosis
Biological products
Blood lipids
Lovastatin
Medicine
Organic Chemistry
Pharmacology/Toxicology
Pharmacy
Triglycerides
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The cycloartane glycosides cyclocarposide and cyclosieversioside F prevent an increase in the blood serum contents of cholesterol, triglycerides, and total fraction of pre-β- and β-lipoproteins in rabbits with atherosclerosis. They increase the ratio of α-cholesterol to total cholesterol and reduce the calculated coefficient of atherogenicity and the ratio of the total fraction of pre-β- and β-lipoproteins to α-cholesterol. In addition, the cycloartane glycosides restore the activity of antioxidant and NO-ergic systems in the heart muscle that is reduced in rabbits with atherosclerosis. The investigated cycloartane glycosides (especially cyclocarposide) had antiatherosclerotic action inferior to that of lovastatin, a drug from the statin group, and had certain advantages over lovastatin with respect to their effects on the antioxidant and NO-ergic systems.
ISSN:0091-150X
1573-9031
DOI:10.1007/s11094-022-02680-5